I have read the Nature Medicine publication and some points bugs me:
Drop out rates were: placebo (58.7%), LY2140023 (33.7%) and olanzapine (20.6%). The placebo group was significantly worse. However, if the adverse events with the new drug were better than why the higher drop out rate? Moreover, the paper does not specify the reason for discontinuation in the LY2140023 group.
Also noted a significant increase in emotional lability in the LY2140023 group, Not a desired outcome in psychotic patients.
Last note is the trial was only 4 weeks long, makes me wonder if Lilly knew that a 6 weeks trial will show significant drop out rates for their compound.
Maybe I'm more suspicious with Lilly after the Zyprexa case but those points are disturbing.
P.S If anyone wants the full article, I still have it.
News 
Market Data 
Discover 
